The increased cardiovascular risk associated with HNF1A-diabetes provides another reason that carefully designed larger, long-term comparison studies of glycemic and cardiovascular outcomes of these newer classes of diabetes medications, which offer cardiovascular benefit, are needed124–126. The gene discussed is HNF1A; the disease is diabetes mellitus.